Novel anti‑hepatitis B virus‑active catechin and epicatechin from Rhus tripartita

  • Authors:
    • Mohammad K. Parvez
    • Mohammed S. Al‑Dosari
    • Mazin A. S. Abdelwahid
    • Ali S. Alqahtani
    • Abdullah R. Alanzi
  • View Affiliations

  • Published online on: April 15, 2022     https://doi.org/10.3892/etm.2022.11325
  • Article Number: 398
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bioactive natural or phytoproducts have emerged as a potential source of antiviral agents. Of the Rhus spp., R. coriaria and R. succedanea have been reported for their antiviral activities against hepatitis B virus (HBV), while the anti‑HBV efficacy of R. tripartita has remained elusive. In the present study, the anti‑HBV activities of R. tripartita‑derived novel catechin [3,5,13,14‑flavantetrol‑catechin or rhuspartin (RPT)] and epicatechin‑3‑O‑rhamnoside (ECR), were assessed using the HBV‑reporter cell line HepG2.2.15. RPT and ECR proved to efficiently inhibit HBV surface antigen (HBsAg) synthesis by 68.8 and 71.3%, respectively, and HBV pre‑core antigen (HBeAg) production by 62.3 and 71.2%, respectively, after 5 days of treatment. Of note, RPT had a lower anti‑HBV activity than ECR. In comparison, the reference drug lamivudine (LAM) inhibited HBsAg and HBeAg expression by 83.6 and 85.4%, respectively. Further molecular docking analysis revealed formations of strong complexes of RPT, ECR and LAM with HBV polymerase through interactions with binding pocket residues. Taken together, the present results demonstrated promising therapeutic potential of the novel R. tripartita‑derived catechin and epicatechin for HBV, warranting their further molecular and pharmacological evaluation.

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Parvez MK, Al‑Dosari MS, Abdelwahid MA, Alqahtani AS and Alanzi AR: Novel anti‑hepatitis B virus‑active catechin and epicatechin from <em>Rhus tripartita</em>. Exp Ther Med 23: 398, 2022
APA
Parvez, M.K., Al‑Dosari, M.S., Abdelwahid, M.A., Alqahtani, A.S., & Alanzi, A.R. (2022). Novel anti‑hepatitis B virus‑active catechin and epicatechin from <em>Rhus tripartita</em>. Experimental and Therapeutic Medicine, 23, 398. https://doi.org/10.3892/etm.2022.11325
MLA
Parvez, M. K., Al‑Dosari, M. S., Abdelwahid, M. A., Alqahtani, A. S., Alanzi, A. R."Novel anti‑hepatitis B virus‑active catechin and epicatechin from <em>Rhus tripartita</em>". Experimental and Therapeutic Medicine 23.6 (2022): 398.
Chicago
Parvez, M. K., Al‑Dosari, M. S., Abdelwahid, M. A., Alqahtani, A. S., Alanzi, A. R."Novel anti‑hepatitis B virus‑active catechin and epicatechin from <em>Rhus tripartita</em>". Experimental and Therapeutic Medicine 23, no. 6 (2022): 398. https://doi.org/10.3892/etm.2022.11325